Larimar Therapeutics, Inc. (LRMR)
NASDAQ: LRMR · Real-Time Price · USD
4.400
-0.040 (-0.90%)
At close: Apr 28, 2026, 4:00 PM EDT
4.490
+0.090 (2.05%)
After-hours: Apr 28, 2026, 7:31 PM EDT
Larimar Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Larimar Therapeutics stock have an average target of 16.5, with a low estimate of 7.00 and a high estimate of 26. The average target predicts an increase of 275.00% from the current stock price of 4.40.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 20, 2026.
Analyst Ratings
The average analyst rating for Larimar Therapeutics stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 3 | 3 | 3 | 3 | 2 |
| Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 7 | 7 | 7 | 7 | 7 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Maintains $12 → $13 | Buy | Maintains | $12 → $13 | +195.45% | Mar 20, 2026 |
| Wedbush | Wedbush | Buy Maintains $11 → $12 | Buy | Maintains | $11 → $12 | +172.73% | Mar 3, 2026 |
| Citigroup | Citigroup | Strong Buy Maintains $12 → $14 | Strong Buy | Maintains | $12 → $14 | +218.18% | Feb 25, 2026 |
| Wedbush | Wedbush | Buy Reiterates $11 | Buy | Reiterates | $11 | +150.00% | Feb 25, 2026 |
| Oppenheimer | Oppenheimer | Buy Maintains $26 → $21 | Buy | Maintains | $26 → $21 | +377.27% | Oct 2, 2025 |
Financial Forecast
Revenue This Year
3.31M
Revenue Next Year
63.39M
from 3.31M
Increased by 1,816.14%
EPS This Year
-2.07
from -2.27
EPS Next Year
-1.57
from -2.07
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 17.0M | 200.9M | ||||||
| Avg | 3.3M | 63.4M | ||||||
| Low | n/a | 4.5M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | 5,972.2% | ||||||
| Avg | - | 1,816.1% | ||||||
| Low | - | 37.2% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -1.45 | -0.70 | ||||||
| Avg | -2.07 | -1.57 | ||||||
| Low | -2.89 | -2.90 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.